Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hope

Showing results (711-720 of 795) with videos related to

Pageof 80
Sort By:
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2022
Imaging joint infections using D-methyl-<sup>11</sup>C-methionine PET/MRI: initial experience in humansIlona Polvoy, Youngho Seo, Matthew Parker, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine TumorsThomas A Hope, Emily K Bergsland, Murat Fani Bozkurt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Pilot and Feasibility Studies|September 19, 2022
Functional, imaging, and respiratory evaluation (FIRE) of patients post-hospitalization for COVID-19: protocol for a pilot observational studyKirby P Mayer, Jessica A Palakshappa, Ithan Daniel Peltan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialWolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
British Journal of Cancer|May 19, 2023
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomasNitya Raj, Jennifer A Chan, Stephanie J Wang, et al.
Science (New York, N.Y.)|April 3, 2025
Strain-induced rubidium incorporation into wide-bandgap perovskites reduces photovoltage lossLikai Zheng, Mingyang Wei, Felix T Eickemeyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION DataVishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Pageof 80

Showing results (711-720 of 795) with videos related to

Sort By:
Pageof 80
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2022
Imaging joint infections using D-methyl-<sup>11</sup>C-methionine PET/MRI: initial experience in humansIlona Polvoy, Youngho Seo, Matthew Parker, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine TumorsThomas A Hope, Emily K Bergsland, Murat Fani Bozkurt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Pilot and Feasibility Studies|September 19, 2022
Functional, imaging, and respiratory evaluation (FIRE) of patients post-hospitalization for COVID-19: protocol for a pilot observational studyKirby P Mayer, Jessica A Palakshappa, Ithan Daniel Peltan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialWolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
British Journal of Cancer|May 19, 2023
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomasNitya Raj, Jennifer A Chan, Stephanie J Wang, et al.
Science (New York, N.Y.)|April 3, 2025
Strain-induced rubidium incorporation into wide-bandgap perovskites reduces photovoltage lossLikai Zheng, Mingyang Wei, Felix T Eickemeyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION DataVishnu Murthy, Andrew F Voter, Kathleen Nguyen, et al.
Pageof 80